Q3 fy23 business update webinar notification

Melbourne, australia, april 11, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to advise it will provide a business update for the quarter ended 31 march 2023 (q3 fy23).
IMRN Ratings Summary
IMRN Quant Ranking